Transcriptomics

Dataset Information

0

Adrenocortical Carcinoma Gene Expression Profiling [Affymetrix]


ABSTRACT: Background: Adrenocortical carcinoma (ACC) is associated with poor survival rates. The objective of the study was to analyze ACC gene expression profiling data prognostic biomarkers and novel therapeutic targets. Methods: 44 ACC and 4 normal adrenal glands were profiled on Affymetrix U133 Plus 2 expression microarrays and pathway and transcriptional enrichment analysis performed. Protein levels were determined by western blot. Drug efficacy was assessed against ACC cell lines. Previously published expression datasets were analyzed as validation data sets. Results: Pathway enrichment analysis identified marked dysregulation of cyclin-dependent kinases and mitosis. Over-expression of PTTG1, which encodes securin, a negative regulator of p53, was identified as a marker of poor survival. Median survival for patients with tumors expressing high PTTG1 levels (log2 ratio of PTTG1 to average beta-actin <-3.04 ) was 1.8 years compared to 9.0 years if tumors expressed lower levels of PTTG1 (P<0.0001). These findings were confirmed by our analysis of previously published datasets. Treatment of ACC cell lines with vorinostat decreased securin levels and inhibited cell growth (IC50s of 1.69 uM and 0.891 uM, for SW-13 and H295R, respectively). Conclusion: Over-expression of PTTG1 is correlated with poor survival in ACC. PTTG1/securin is a prognostic biomarker and warrants investigation as a therapeutic target.

ORGANISM(S): Homo sapiens

PROVIDER: GSE19750 | GEO | 2013/11/21

SECONDARY ACCESSION(S): PRJNA123999

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-11-21 | E-GEOD-19750 | biostudies-arrayexpress
2013-11-21 | GSE19775 | GEO
2013-11-21 | E-GEOD-19775 | biostudies-arrayexpress
2021-09-07 | PXD027404 | Pride
2023-02-08 | GSE214969 | GEO
2019-07-01 | GSE124531 | GEO
2016-03-07 | GSE77871 | GEO
2013-07-31 | E-GEOD-25493 | biostudies-arrayexpress
2023-03-10 | ST002395 | MetabolomicsWorkbench
2024-10-21 | GSE277486 | GEO